Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Agenus
Biotech
BMS ditches TIGIT, ending $200M bet on Agenus bispecific
BMS is axing another big bet from the Caforio era, terminating a deal for Agenus' TIGIT bispecific after paying $200 million to buy into the program.
Nick Paul Taylor
Aug 5, 2024 9:17am
FDA wrecks Agenus’ accelerated approval plan
Jul 18, 2024 8:01am
BMS trims anti-TIGIT and a handful of other meds
Sep 14, 2023 1:57pm
Agenus lays off 25%, sidelines programs to focus on cancer combo
Aug 23, 2023 11:04am
Agenus gets boost for combo drug, this time in ovarian cancer
Mar 27, 2023 9:45am
Combo may offer route back for Agenus' cervical cancer drug
Jan 23, 2023 10:47am